Go here to read the rest:
Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress
Related Post
- Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119... - May 29th, 2024
- Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain - May 29th, 2024
- InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical... - May 29th, 2024
- Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors - May 29th, 2024
- Annual General Meeting of Ipsen S.A. held on 28 May 2024 - May 29th, 2024
- Mithra postpones its annual general meeting - May 29th, 2024
- Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes - May 29th, 2024
- Acasti Pharma to Attend BIO International Convention 2024 - May 29th, 2024
- Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference - May 29th, 2024
- Cellectis Reports Financial Results for First Quarter 2024 - May 29th, 2024
- NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical... - May 29th, 2024
- Cronos Terminates Sale-Leaseback of Peace Naturals Campus - May 29th, 2024
- UPDATE – Ikena Oncology Announces Strategic Update - May 29th, 2024
- FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation - May 29th, 2024
- 1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China - May 29th, 2024
- Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study - May 29th, 2024
- Burning Rock Reports First Quarter 2024 Financial Results - May 29th, 2024
- Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each... - May 29th, 2024
- Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication - May 29th, 2024
- Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer - May 29th, 2024
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024... - May 27th, 2024
- HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting - May 27th, 2024
- Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting - May 27th, 2024
- Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - May 27th, 2024
- Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 27th, 2024
- Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024 - May 27th, 2024
- Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 - May 27th, 2024
- Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications - May 27th, 2024
- Changes to the Roche Enlarged Corporate Executive Committee - May 27th, 2024
- Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland,... - May 27th, 2024
- Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma - May 27th, 2024
- Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover - May 27th, 2024
- Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 - May 27th, 2024
- BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the... - May 27th, 2024
- Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - May 25th, 2024
- Minutes of Annual General Meeting 2024 - May 25th, 2024
- Monopar Announces CFO Succession - May 25th, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid... - May 25th, 2024
- IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - May 25th, 2024
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 25th, 2024
- Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 25th, 2024
- Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company - May 25th, 2024
- BioSenic provides First Quarter 2024 Business Update - May 25th, 2024
- Purespring Therapeutics presents preclinical data at the 61st ERA Congress - May 25th, 2024
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - May 25th, 2024
- Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - May 25th, 2024
- Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. - May 25th, 2024
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events - May 25th, 2024
- Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome - May 25th, 2024
- Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting - May 25th, 2024
- OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - May 25th, 2024
- Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - May 25th, 2024
- Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically... - May 25th, 2024
- Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - May 25th, 2024
- Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in... - May 23rd, 2024
- Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in... - May 23rd, 2024
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting - May 23rd, 2024
- IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting - May 23rd, 2024
- Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid... - May 23rd, 2024
- Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress - May 23rd, 2024
- Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024... - May 23rd, 2024
- HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting - May 23rd, 2024
- Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in... - May 23rd, 2024
- Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be... - May 23rd, 2024
- BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology... - May 23rd, 2024
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated... - May 23rd, 2024
- NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of... - May 23rd, 2024
- I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - May 23rd, 2024
- Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the... - May 23rd, 2024
- FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with... - May 23rd, 2024
- Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - May 23rd, 2024
- Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting - May 23rd, 2024
- G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting - May 23rd, 2024
- BioSyent Releases Financial Results for Q1 2024 - May 19th, 2024
- BioSyent Declares Second Quarter 2024 Dividend - May 19th, 2024
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 19th, 2024
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 19th, 2024
- Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - May 19th, 2024
- QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 19th, 2024
Recent Comments